Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT03404362 Completed - Bone Metastases Clinical Trials

MRgFUS Versus EBRT in Patients With Metastatic Non-spinal Bone Disease

Start date: April 2010
Phase: N/A
Study type: Interventional

The objective of this trial is to collect and compare safety and effectiveness data of Magnetic Resonance guided Focused Ultrasound (MRgFUS) using the ExAblate 2100 device and radiotherapy in the treatment of metastatic bone tumors. This study is designed as a prospective, double arm, randomized study with External Beam radiation therapy (EBRT) serving as control arm. The study hypothesis is that MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT.

NCT ID: NCT03401814 Not yet recruiting - Liver Metastases Clinical Trials

Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases

Start date: January 2018
Phase: N/A
Study type: Observational

Patients will be imaged with MRE at the time of the RT planning MRI, prior to the induction of RT and immunotherapy. Research imaging will be in addition to standard imaging studies performed at time points consistent with the standard of care (at the time of the RT planning MRI and the first clinical follow-up). An additional MRE exam will be performed at the end of treatment outside the standard of care imaging.

NCT ID: NCT03398694 Not yet recruiting - Brain Metastases Clinical Trials

Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases

Start date: February 28, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, phase II trial to determine the local control at 6 months utilizing pre-operative stereotactic radiosurgery followed by surgery within 1 - 3 days in subjects with a diagnosis of 1-4 brain metastases and with an indication for surgical resection of at least one brain metastasis at the discretion of a neurosurgeon.

NCT ID: NCT03398512 Recruiting - Clinical trials for Peritoneal Metastases From Colorectal Cancer

HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The prognosis of patients with unresectable peritoneal metastases from colorectal cancer is poor. These patients may obtain survival benefit from radical colorectal resection and cytoreductive surgery (CRS). The response rates of previous conversion therapy are low. Hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective methods of reducing peritoneal cancer index (PCI) levels. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy in the conversion therapy of peritoneal metastases from colorectal cancer.

NCT ID: NCT03396211 Recruiting - Cancer Clinical Trials

Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer

Start date: December 22, 2017
Phase: Phase 1
Study type: Interventional

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of adding apatinib to ongoing nivolumab treatment in patients with unresectable or metastatic cancer. Approximately 9-18 subjects in Phase I dose escalation phase and up to 12 additional subjects in Part II expansion phase. Total study duration will be approximately 12 months: 6 months of recruitment plus 6 months of treatment.

NCT ID: NCT03392428 Not yet recruiting - Metastatic Cancer Clinical Trials

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

TheraP
Start date: January 2018
Phase: Phase 2
Study type: Interventional

This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer

NCT ID: NCT03392233 Recruiting - Breast Cancer Clinical Trials

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

Start date: August 18, 2017
Phase: Phase 2
Study type: Interventional

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

NCT ID: NCT03391479 Not yet recruiting - Metastatic Cancer Clinical Trials

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

Start date: February 1, 2018
Phase: Phase 2
Study type: Interventional

This is a phase 2 study whose purpose is see how useful investigational drug, avelumab, is in patients with locally advanced or metastatic penile cancer who are unfit for or progressed on platinum-based chemotherapy. The usefulness of avelumab in this study population will be determined by anti-tumor activity assessed by objective response rate. Avelumab is a monoclonal antibody that binds to a protein called programmed death-ligand 1 (PD-L1) and blocks its communication with another protein called programmed death protein 1 (PD-1). The communication of these proteins are thought to be important in the growth of tumors. Blocking these proteins from communicating may stop or shrink tumors.

NCT ID: NCT03391362 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-6 Brain Metastases

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-6 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

NCT ID: NCT03387670 Not yet recruiting - Clinical trials for Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis-Simvastatin Trial 2

MS-STAT2
Start date: January 2018
Phase: Phase 3
Study type: Interventional

Multiple Sclerosis (MS) is a progressive neurological disorder of the brain and spinal cord. It affects approximately 120,000 people in the United Kingdom and 2.5 million people globally. Most people with MS experience two stages of the disease: Early MS - Relapsing-Remitting MS (RRMS), which is partially reversible, and Late MS - Secondary Progressive MS (SPMS), which affects the majority of patients, usually after 10 to 15 years after diagnosis. SPMS results from progressive neuronal degeneration that causes accumulating and irreversible disability affecting walking, balance, manual function, vision, cognition, pain control, bladder and bowel function. The pathological process driving the accrual of disability in SPMS is not known at present. Immunomodulatory anti-inflammatory disease modifying therapies (DMTs) are increasingly effective in reducing relapse frequency in RRMS, however, they have been unsuccessful in slowing disease progression in SPMS. This is the overwhelming conclusion from an analysis of 18 phase 3 trials (n=8500), of which 70% of the population had SPMS, all performed in the last 25 years. There is no current disease modifying treatment (DMT) for SPMS. In an earlier study (Multiple Sclerosis-Simvastatin 1; MS-STAT1), 140 people with SPMS were randomly assigned to receive either placebo or simvastatin for a period of two years. The investigators found that the rate of brain atrophy (loss of neurons - 'brain shrinkage'), as measured by magnetic resonance imaging (MRI), was reduced in patients receiving simvastatin compared to those taking placebo. Several other long term studies have also reported that there might be a relationship between the rate of brain atrophy and the degree of impairment. The study is designed to test the effectiveness of repurposed simvastatin (80mg) in a phase 3 double blind, randomised, placebo controlled trial (1:1) in patients with secondary progressive MS (SPMS), to determine if the rate of disability progression can be slowed over a 3 year period. The results generated from this trial may help to improve the treatment options of people with MS. In addition, taking part in this trial will mean regular review by an experienced neurologist regardless of the drug that patients are randomly allocated to receive.